Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Behind The Approval Letter: Drug Review Profiles

May 16 2016

• By Bridget Silverman

Related Content

<em>Zarxio</em> Syringe’s Limitations May Delay Decision On <em>Neupogen</em> Interchangeability

Jun 15 2015

FDA’s Inaugural Biosimilar Review Bumpier Than First Appeared

Jun 15 2015

How To Label A Biosimilar? Copy The Reference Product, FDA Told Sandoz

Jun 15 2015

Sandoz’s Biosimilar Data-Bridging Plans For <em>Zarxio</em> Faced FDA Doubts

Jun 15 2015

Sorry, Wrong Email: FDA’s ‘Oops’ Moment In The <em>Zarxio</em> Review

Jun 15 2015

<em>Zarxio</em> Clinical Development Timeline

Jun 15 2015

<em>Zarxio</em> Reviewers

Jun 15 2015

Liver Injury Case Sparked Flurry Of Concern Late In <em>Praluent</em> Review

Jan 18 2016

<em>Repatha</em> Was Almost Derailed By Formulation Bridging Concerns

Jan 18 2016

<em>Praluent</em> Sponsors Set Tone For PCSK9 Labeling, Post-Marketing Negotiations

Jan 18 2016

How Many People Can Squeeze Into A Mid-Cycle Meeting? For <em>Savaysa</em>, The Number Is 70

Apr 27 2015

<em>Savaysa</em> Shows The Good And Bad Of Being Late In Class

Apr 27 2015

<em>Savaysa</em> A-Fib Data Led To Conflicting FDA Views On Dose, Population

Apr 20 2015

Kythera Claims <em>Kybella</em> Name After Lundbeck Stumbles With <em>Carbella</em>

Sep 21 2015

<em>Kybella</em> Approval Shows How To Work With FDA On Clinical Outcome Assessments

Sep 21 2015

Patient-Reported Outcomes Data Earned <em>Kybella</em> A Claim For Emotional Impacts

Sep 21 2015

Chin Fat Not A 'Serious Condition' Worthy Of Priority Review, FDA Says

Sep 21 2015

More from Archive

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window